InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...
Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback